Cita APA (7a ed.)
Wang, N., Mo, Z., Pan, L., Zhou, M., Ye, X., Liu, X., . . . Li, W. (2023). Dual PI3K/HDAC Inhibitor BEBT-908 Exhibits Potent Efficacy as Monotherapy for Primary Central Nervous System Lymphoma. Targeted Oncology, 18(6), 941-953.
Cita Chicago Style (17a ed.)
Wang, Ning, et al. "Dual PI3K/HDAC Inhibitor BEBT-908 Exhibits Potent Efficacy as Monotherapy for Primary Central Nervous System Lymphoma." Targeted Oncology 18, no. 6 (2023): 941-953.
Cita MLA (9a ed.)
Wang, Ning, et al. "Dual PI3K/HDAC Inhibitor BEBT-908 Exhibits Potent Efficacy as Monotherapy for Primary Central Nervous System Lymphoma." Targeted Oncology, vol. 18, no. 6, 2023, pp. 941-953.
Precaución: Estas citas no son 100% exactas.